Rare disease company EnBiotix merges with Swiss firm

EnBiotix Inc., a Boston-based biotech focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. Under the terms of the agreement, Polyphor will acquire all of EnBiotix's outstanding capital stock; EnBiotix will in turn acquire the rights to inhaled murepavadin, a potent antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in cystic fibrosis patients, for $10 million . The merger is expected to close in the fourth quarter…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news